Walleye Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-28,200
| Closed | -$2.88M | – | 5509 |
|
|
2023
Q2 | $2.88M | Sell |
28,200
-62,900
| -69% | -$5.95M | 0.01% | 1382 |
|
|
2023
Q1 | $8.28M | Buy |
91,100
+85,900
| +1,652% | +$5.04M | 0.02% | 717 |
|
|
2022
Q4 | $198K | Sell |
5,200
-27,000
| -84% | -$929K | ﹤0.01% | 3580 |
|
|
2022
Q3 | $809K | Buy |
32,200
+24,700
| +329% | +$685K | ﹤0.01% | 2431 |
|
|
2022
Q2 | $228K | Buy |
+7,500
| New | +$224K | ﹤0.01% | 3591 |
|
|
2022
Q1 | – | Sell |
-2,000
| Closed | -$53K | – | 6083 |
|
|
2021
Q4 | $53K | Sell |
2,000
-2,200
| -52% | -$170K | ﹤0.01% | 4659 |
|
|
2021
Q3 | $423K | Buy |
4,200
+2,900
| +223% | +$340K | ﹤0.01% | 3094 |
|
|
2021
Q2 | $184K | Buy |
+1,300
| New | +$147K | ﹤0.01% | 3994 |
|
|
2020
Q4 | – | Sell |
-1,300
| Closed | -$127K | – | 5035 |
|
|
2020
Q3 | $127K | Buy |
1,300
+500
| +63% | +$62.5K | ﹤0.01% | 3280 |
|
|
2020
Q2 | $125K | Sell |
800
-200
| -20% | -$30.4K | ﹤0.01% | 3384 |
|
|
2020
Q1 | $144K | Sell |
1,000
-6,900
| -87% | -$1.33M | ﹤0.01% | 2873 |
|
|
2019
Q4 | $1.61M | Buy |
7,900
+7,200
| +1,029% | +$1.31M | 0.01% | 1381 |
|
|
2019
Q3 | $56K | Sell |
700
-1,400
| -67% | -$119K | ﹤0.01% | 3534 |
|
|
2019
Q2 | $198K | Sell |
2,100
-100
| -5% | -$8.63K | ﹤0.01% | 2951 |
|
|
2019
Q1 | $188K | Sell |
2,200
-100
| -4% | -$8.3K | ﹤0.01% | 3075 |
|
|
2018
Q4 | $129K | Buy |
2,300
+100
| +5% | +$6.11K | ﹤0.01% | 3739 |
|
|
2018
Q3 | $180K | Buy |
2,200
+2,100
| +2,100% | +$148K | ﹤0.01% | 3843 |
|
|
2018
Q2 | $3K | Buy |
+100
| New | +$3.05K | ﹤0.01% | 4486 |
|
Other funds holding RETA
Walleye Trading's RETA Position: Q3 2022 in Review
Walleye Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 5,251 shares — an estimated $146K sold.
Walleye Trading first reported a position in RETA in Q4 2016 and held it in 9 quarters. The position peaked at $289K in Q3 2019. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.
- Walleye Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
- Walleye Trading sold 5,251 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $146K.
- Walleye Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 9 quarters.
- Walleye Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $289K in Q3 2019.
- 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.
Based on Walleye Trading's 13F filing for Q3 2022, filed 14 Nov 2022.